
Genmab's three winning horses may very well turn into five in the course of 2021.
"The most important milestone this year is that we hope to get two new products approved, which are basically created with Genmab techology. One is Johnson & Johnson's Amivantamab, and the other is Tisotumab Vedotin," Genmab CEO Jan van de Winkel tells Ritzau Finans.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app